Why the study?
Visceral adiposity is a major cardiometabolic risk factor, but imaging-based measurement of visceral adipose tissue presents financial and practical challenges for population-based studies.
Does higher estimated visceral adipose tissue measured by an anthropometric index associate with an increased risk of cardiometabolic conditions in a general population?
Does higher estimated visceral adipose tissue measured by an anthropometric index associate with an increased risk of cardiometabolic conditions in a general population?
An easily measurable anthropometric index for visceral adipose tissue is strongly associated with increased odds of cardiometabolic conditions, highlighting its potential utility when biomedical imaging is unavailable.
May aid cardiometabolic risk stratification without imaging; leaves open causality and prospective utility.
Visceral adiposity is a major risk factor of cardiometabolic diseases. Visceral adipose tissue (VAT) is usually measured with expensive imaging techniques which present financial and practical challenges to population-based studies. We assessed whether cardiometabolic conditions were associated with VAT by using a new and easily measurable anthropometric index previously published and validated. Data (1529 participants) came from the European Health Examination Survey in Luxembourg (2013-2015). Logistic regressions were used to study associations between VAT and cardiometabolic conditions. We observed an increased risk of all conditions associated with VAT. The total adjusted odds ratio (AOR, [95% CI]) for hypertension, prediabetes/diabetes, hypercholesterolemia, and hypertriglyceridemia for the fourth quartile of VAT compared to the lowest were (10.67 [6.95, 16.39]), (6.14 [4.14, 9.10]), (6.03 [3.97, 9.16]) and (9.18 [5.97, 14.12]). We observed higher odds in women than in men for all outcomes with the exception of hypertension. Future studies should investigate the impact of VAT changes on cardiometabolic health and the use of anthropometrically predicted VAT as an accurate outcome when no biomedical imaging is available.
No takes yet. Share an insight, caveat, or question.
Ruiz‐Castell et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: